Designation reflects serious unmet need in idiopathic pulmonary fibrosis (IPF), where approved therapies slow but do not halt disease ...

TAG Therapeutics a biotechnology company developing precision medicines for diseases driven by telomere dysfunction, today announces the publication of compelling preclinical data supporting the ...

Early diagnosis and treatment in IPF and PPF are vital, as fibrosis is irreversible and current therapies only slow progression. Current IPF treatments, pirfenidone and nintedanib, have significant ...

IPF is a rare, progressive and fatal lung disease with a median survival of 2-5 years. 1 Pirfenidone is one of only two drugs approved to treat IPF, and for those patients able to tolerate treatment, ...

Dr Nathan discusses the trajectory of IPF management. How do you envision these investigational agents potentially being implemented into future treatment paradigms for idiopathic pulmonary fibrosis ...

Trevi Therapeutics leverages Haduvio's dual mechanism to target IPF-related chronic cough. Click here to read why TRVI stock ...

Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks! Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks An announcement from PureTech Health ...

HealthDay News — Recommendations for idiopathic pulmonary fibrosis (IPF) treatment have been updated by an international group of respiratory societies. The updated clinical practice guideline was ...

Idiopathic pulmonary fibrosis (IPF) is a rapidly progressive, fatal disease of unknown cause. Although there is no known cure, there have been indications that gastroesophageal reflux disease (GERD) ...

This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Gersten: I've ...

Dublin, May 19, 2026 (GLOBE NEWSWIRE) -- The "Idiopathic Pulmonary Fibrosis Market by Therapy; Region - Market Size, Industry Dynamics, Opportunity Analysis and Forecast for 2026-2035" report has been ...

The emerging role of precision medicine in diagnosing and treating interstitial lung disease will take center stage during ...